Every record, read against the news each week

Nothing in the window. The searches returned only the 2020 UBX0101 failure the record already holds and the fisetin trials. One of those, named ROPE (registry number NCT04770064, 74 adults aged 40 to 80 with knee osteoarthritis, two fisetin dose schedules against placebo), is a different registry entry from the one the record's notes name (NCT04210986, 75 people, Steadman Philippon), and a supplement retailer's page says ROPE found no benefit over placebo on either schedule, with results in a conference-proceedings issue of Osteoarthritis and Cartilage; that rests on secondary reporting, has no date seen, and a null result would not move the leaf, so it is offered here only as something the notes might name once checked. A 2025 mouse paper on an intra-joint senolytic prodrug (SSK1) is animal work the leaf already stands on.

Nothing in the window. Both searches returned only the 2016 engineered-mouse result and the 2018 dasatinib-plus-quercetin result (36 per cent longer remaining life in old mice) that the record already holds, and no human trial with a lifespan or healthy-years measure was found proposed or started. The session's search budget ran out before a third query could be run for this leaf.

Nothing in the window of the settler's kind: no registry entry, no first person treated, and no peer-reviewed report of engineered immune cells given to a person. A Medscape news piece dated 2026-10-14 reviews senolytic CAR T cells and says they remain preclinical with no approved therapy, which is press and confirms the stage rather than moving it. The same group's 2026 Cell paper (Zhang, Filliol, Sadelain, Lowe and colleagues, published 2026-03 by the repository address) turns uPAR-directed CAR T cells on solid tumours in mice, not on aged cells in a person, and is outside the window. The Cedars-Sinai PD-L2 paper (press release 2026-09-10) is about how aged cells hide from the immune system in mice and human samples, not about engineered cells.

Nothing in the window. Every result was the 2024-02-29 release, its 2024-03-05 correction, the SkeptVet review of 2024-02 and trade coverage of the North Carolina State study, still described as a bioRxiv preprint submitted for review; no peer-reviewed version and no new statement by Sinclair or the company was seen, and the company's own site could not be opened. The verdict missed stands.

Nothing in the window 2026-10-10 to 2026-10-17. The nearest things seen were all older and all short of the test's clinic rung, which needs a regulator's approval: the National Institutes of Health low-dose danazol study in telomere disease (registry number NCT03312400) was last changed on 2026-05-29 and is listed as running to 2027-10-29 with no result posted, and a French multicentre trial of danazol in people carrying telomere-gene faults with lung scarring or marrow failure (the ANDROTELO study) was published in 2025 in ERJ Open Research, which the leaf does not name but which does not change the rung either way. The peer-reviewed Blood Advances version of the 2024 long-term follow-up that the leaf's verify list names could not be confirmed or ruled out, because no publisher page would open and the search did not surface it.

Nothing in the window 2026-10-10 to 2026-10-17 was seen, and nothing bearing on this leaf's first-human rung, which needs the mutation behind a premature-ageing disease corrected and measured in a person. This verdict is weaker than the others and should not be relied on: the turn's shared web-search budget ran out before any search aimed at this leaf could be run, so it rests on two borrowed searches, which the brief says do not count towards the floor of two. No search was run for a progeria base-editing trial, for the single-patient route the leaf's estimate turns on, or for the group that published the 2021 mouse result.

No search aimed at this leaf could be run: session's search allowance (200 searches, shared by the twelve searchers of this first reading) ran out before a second search aimed at this record could be run. It rests on two searches borrowed from the other leaves of its branch, so its quiet verdict is weaker than the others and it is read first at the next reading.

Nothing in the window. The one search that ran returned the 2009 Publishers Weekly review of the book, which paraphrases the promise as DNA reprogramming and cell-repairing nanorobots within the next twenty or so years (a corroborating secondary source the record does not cite, dated 2009, not a finding), and publisher and bookseller listings. The second search, on his 2026 statements about nanorobots and reprogramming by 2029, was refused because the shared search budget was exhausted, so this record had one search instead of the two the brief asks for; the 2026 restatement of the date to around 2032 reported under kurzweil-2029-escape-velocity bears on this record too, since the due year is 2029.

The session's search allowance (200 searches, shared by the twelve searchers of this first reading) ran out before a second search aimed at this record could be run.

Only one search could be run on 2026-10-17 and the company site could not be opened. The search returned Wikipedia, Discover and Fight Aging background on the 2015 dosing and the 2016 release, and a Medium piece titled as a ten-years-after interview, with no date visible in the result; nothing dated in the window. The public record paragraph still holds on what was seen.

The session's search allowance (200 searches, shared by the twelve searchers of this first reading) ran out before a second search aimed at this record could be run.

Nothing in the window. The most recent human data on the tool this leaf tracks (Tune Therapeutics' TUNE-401 epigenetic silencer) remains the proof-of-concept presented at the European liver congress on 2026-05-30, which the record already carries and which is a conference presentation, not the peer-reviewed report or posted registry results the settler requires. No peer-reviewed paper or registry-posted result appeared in the window, and no application of the tool to an ageing gene in a person was found, so the leaf stays at the animal rung.

Nothing in the window. No peer-reviewed report appeared of a small-molecule cocktail, with no genes delivered, moving an age marker towards youth in a living mammal. Searches surfaced only older work the record already knows or that falls short: the 2023 Harvard cell-culture study (journal Aging), a 2022 worm preprint, and a 2024 Frontiers in Aging mouse study that combined small molecules with the Yamanaka genes rather than using a cocktail alone. The leaf stays at idea only.

Nothing in the window. No peer-reviewed, controlled trial appeared showing a validated DNA-mark clock turned back in a person. The controlled follow-up to the 2019 trial (TRIIM-X) has its results only in a Foresight Institute talk and a secondary Lifeboat Foundation summary dated 2026-06, both before the window and neither peer-reviewed; its registry entry was last updated in 2025-05 with no results posted, which the record's verify list already flags. The searches did not settle whether TRIIM-X is still running. The leaf stays at first human.

Nothing in the window. The nearest items are a company-profile report by Sacra (dated 2026-09 in the result) saying Altos still had no named clinical candidate, no investigational new drug filing and no company-run human trial, and a fightaging.org post of 2026-05 on the company becoming less secretive; both are outside the window, both are third-party, and neither touches a claim that names no date and no treatment. The company's own newsroom could not be opened.

Nothing in the window. The company's two October releases both fall before it: on 2026-10-01 it announced the Eyecelerator oral presentation for 2026-10-08, and on 2026-10-08 it reported the three-participant interim data the record already holds (well tolerated through day fifty-six, visual-field signals in two, and, which the record does not mention, a data safety monitoring board recommendation to escalate to the second dose level). A lifeboat.com blog repost of the 2026-10-01 release is dated 2026-10 without a day. Nothing changes the verdict of missed, which rests on the start date, not the results; the registry entry for NCT07290244 could not be opened from this session to check for an update in the window.

Nothing in the window. The company's press release index, as summarised in search results, lists five 2026 items, the newest a board appointment of 2026-08-10, after the regulator's clearance of 2026-01-28 (trial NCT07290244), the 80 million dollar financing of 2026-04-08 and the first participant dosed on 2026-06-09; all are in the record. Nothing from the Salk Institute or Izpisua Belmonte in 2026 was seen. The ClinicalTrials.gov entry could not be opened, so the open verify item on the day of first dosing is not settled.

Nothing in the window. Search summaries of the company's press index show no release after 2026-08-10, and no trial result has been published; Fortune (2026-01-30) quoted the chief executive Jerry McLaughlin expecting results by the end of 2026 or early 2027, and coverage of the 2026-06-04 Athens lecture has Sinclair saying the first glaucoma patient had been treated, both before the window and consistent with the record's dates of 2026-01-28 and 2026-06-09. The verdict missed stands.

Nothing in the window. What was seen falls short of the test: a 2026-07 meta-analysis of urolithin A trials in Frontiers in Nutrition (a pooling of older trials, not a new controlled trial, and dated before the window); a registered six-month trial of urolithin A against placebo in middle-aged adults (ClinicalTrials.gov NCT07231783) still recruiting with no result; a 40-person pilot of spermidine on vaccine response in people over 65, which is an immune marker and not an age-related function on a pre-stated main measure; and worm and cell work on new autophagy activators (a bioRxiv preprint of 2026-01). The POLYCAD trial of spermidine in heart disease was described as not yet reported. No regulator's record and no peer-reviewed controlled human trial with a function main measure appeared in the window.

Nothing in the window. All three searches returned only background older than 2026: the 1998 rat record and 2001 human record already on the leaf, the 2014 note that alagebrium had no effect in later human trials, and advocacy-site profiles of Revel Pharmaceuticals (a spin-out of the Spiegel laboratory at Yale developing enzymes that cut glucosepane) with no trial registration, no peer-reviewed animal report and no company release dated 2026. One undated advocacy page says the company has had difficulty reproducing the original glucosepane-cleaving finding and has instead found an enzyme that removes a different sugar adduct (carboxymethyl-lysine); it is not a record of the settler's kind and is not dated, so it is noted here only as a lead for a later reading.

Nothing in the window bears on the wide-use test: no uptake figure, no new approval and no new trial report dated 2026-10-10 to 2026-10-17 was found. The only patient-scale figure seen is Pfizer's 2019 estimate of about 100,000 people with the disease in the United States with one to two per cent diagnosed, which is too old to count. Two things older than the window are not in the leaf and do not change the rung: a gene silencer, eplontersen, missed its main measure of cardiovascular deaths and events against placebo in the CARDIO-TTRansform trial (reported at the European cardiology congress with a New England Journal of Medicine paper; the American College of Cardiology's summary is dated 2026-08-24), which bears on the estimate's expectation that silencers would widen use but leaves the approved silencer vutrisiran in place; and the deposit-clearing antibody ALXN2220's Phase 3 trial (ClinicalTrials.gov NCT06183931) lists an estimated primary completion of 2027-12-06, so the "late-stage trials" line in the description holds. Pfizer's plan to withdraw the low-dose tafamidis capsule in the United States was seen in trade coverage of uncertain date and is a product decision, not an uptake record.

Nothing in the window. The newest items seen were the Fight Aging post of 2026-01 on the start of the Australian safety trial of the autophagy drug RTR242 (registry number ACTRN12625001274460, five dose groups from 50 to 800 milligrams, six on drug and two on placebo per group), Core Memory's report of eight people dosed in mid-December 2025, and the company's own blog post of 2026-05-22 on its financing at a 1.8 billion dollar valuation; the record already carries all of this and the verdict missed stands. The registry entry itself could not be opened to check for a change in the window.

Nothing in the window: no trial reporting longer life or longer disease-free life in people was found dated 2026-10-10 to 2026-10-17. Two older things were seen that the record does not name and that fall short of the test: a Nature Biotechnology report of September 2026 (exact date not seen) that the lung-disease drug rentosertib lowered six ageing-clock readings in 42 patients over twelve weeks, which is a clock result for the measuring branch and not extra years; and the VITAL-H trial announced by UT Health San Antonio on 2026-02-25, funded with up to 38 million dollars by the United States agency ARPA-H, which plans to give rapamycin, dapagliflozin or semaglutide against placebo to 726 adults in their sixties for three years, with a composite of physical and mental function (intrinsic capacity) as its outcome rather than lifespan or time to disease, and which in April 2026 was still waiting for ethics approval. The TAME search is listed under the metformin leaf too; it found no funding news in the window.

The Upgrade Tree shows it at shown in animals, which agrees.

Nothing in the window: no approval, conditional or full, of any dog-lifespan drug was found, and no company post, regulator notice or peer-reviewed trial report dated 2026-10-10 to 2026-10-17. The newest items seen were the company's safety-section acceptance of 2026-01-13, which the record already holds, a report that the company raised a 100 million dollar funding round in February 2026 (funding, not the record), and company pages saying the manufacturing section is the one outstanding step with the application expected in 2027, as the record says. The company's newsroom and the regulator's list of conditional approvals could not be opened from this session (the network refused loyal.com and fda.gov), so the first fact on the verify list, that no regulator had approved such a drug as of 2026-10-17, stays checked by search only.

Nothing in the window: no controlled trial of a mitochondria-renewing or mitochondria-protecting drug on muscle in people was found dated 2026-10-10 to 2026-10-17, and no regulator's approval. The searches returned the trials the record already holds (the 2022 JAMA Network Open trial of 66 older adults with a gain in muscle endurance, and the 2022 Cell Reports Medicine trial in middle-aged adults with a strength gain of about 12 per cent), company material from 2020 to 2022, and a bioRxiv preprint posted 2025-10-30 on the uncoupler BAM15 in animal models of sarcopenia, which is a preprint and an animal result, so it bears on no rung above the one already reached.

Nothing in the window: no peer-reviewed controlled trial of an NAD-raising compound on an age-related function dated 2026-10-10 to 2026-10-17 was found, and no regulator's approval. Older items seen and falling short: a December 2025 pilot of nicotinamide riboside in 52 people with mild cognitive impairment (NAD rose, cognition did not improve); a ClinicalTrials.gov entry (NCT04571008, Effect of NMN Supplementation on Organ System Biology) showing results first posted 2026-03-11 and last updated 2026-08-17, which is a registry posting and not a peer-reviewed report, and whose findings were not visible; and a 2026 company document describing a 66-person trial of nicotinamide riboside with exercise in Friedreich's ataxia, an inherited disease rather than an age-related function. None of these moves the leaf, which is already at first human and whose next rung is a regulator's approval.

Nothing in the window: no trial report, registry change, funding announcement or regulator's step on metformin for ageing dated 2026-10-10 to 2026-10-17 was found. The verify item stays open: the 2026 web pages still disagree (one explainer says enrolment is ongoing; one page updated 2026-06-14 says no one has been enrolled and the trial is stalled for lack of money), both are secondary, and the registry entry could not be opened because this session's network refused clinicaltrials.gov; the registry number NCT04370067 came from a search summary and is itself unchecked. One thing seen that the record does not say, outside the window: the ARPA-H-funded VITAL-H trial announced 2026-02-25 (rapamycin, dapagliflozin, semaglutide; 726 adults; 38 million dollars) does not include metformin, so it does not bear on this leaf's test, though it shows that public money for a healthspan trial of generic drugs has been found once.

Nothing in the window: no peer-reviewed report of a person's tissue function improving after a mitochondrial transplant, and no regulator's approval, dated 2026-10-10 to 2026-10-17 was found. Older items seen and falling short: an Iranian registry entry dated 2026-06-03 for a planned randomised, blinded phase I study of platelet-derived mitochondria in about ten stroke patients (a protocol, safety outcomes only); a phase 1 study of the product MNV-201 in low-risk myelodysplastic syndrome reported at the December 2025 haematology meeting with five patients and no control group; and a 2026 Nature paper on cell-type-targeted mitochondrial transplantation whose functional evidence is from cells and mice. Nothing was found on the Taiwan trial the verify list asks about.

Nothing in the window: no peer-reviewed controlled trial of an mTOR drug at an ageing dose in older people, and no regulator's approval or published clinic practice, dated 2026-10-10 to 2026-10-17 was found. The searches returned the 2025 PEARL trial the record already holds, three registered trials with no results (RESTOR, NCT06658093, a dose-finding study of rapamycin and everolimus in people aged 65 to 90 at San Antonio, described on radio on 2026-05-31; the Everolimus Aging Study, NCT05835999, daily against weekly against placebo; and the Wisconsin RAP PAC phase 1 study, NCT05949658, still enrolling), and an undated preprint reporting lower p21 in immune cells of older adults on rapamycin against placebo, which is not peer-reviewed.

Nothing in the window bears on the start of the trial. The results were the NPR coverage of 2024-04-22 (the trial waits on money) and older background; one page that reads as a machine-written summary asserts that the trial is registered as ongoing in 2026 with nobody enrolled, which is not a primary source and contradicts the record's own check of ClinicalTrials.gov on 2026-10-16. The registry could not be opened on 2026-10-17 to re-check, so the missed verdict stands as written.

Nothing in the window. No approval of LOY-002 or any other Loyal drug was found; the newest company items seen are the posts of 2026-01-13 (safety section accepted) and 2026-02-11 (financing) that the record already holds, and third-party pieces (BroBible, SDP Noticias, presse-citron, a Manifold prediction market) repeat that the manufacturing section is expected to be reviewed in 2027. A Fast Company piece headlined with two hundred and fifty million dollars for Loyal appeared in the results undated and could not be opened; if it is a new round it belongs to the leaf, not this claim, and does not touch the verdict of missed. The company's posts page could not be opened from this session.

Only one search could be run on 2026-10-17 (the shared search budget was then refused) and his protocol page could not be opened. The search returned nothing dated in the window: a Wikipedia summary mentioning a 60 million dollar raise for Blueprint in an October with no year given, and Gyre Renwick named chief executive of Blueprint in 2025-07 (consistent with the record's 2025-07 line), plus several undated or 2026-07-31 content-farm pages giving a pace of ageing of about 0.64 with no source. Nothing in the window bears on the public record paragraph, which still holds on what was seen.

The session's search allowance (200 searches, shared by the twelve searchers of this first reading) ran out before a second search aimed at this record could be run.

Only one search could be run on 2026-10-17. It returned the 2023 Fortune pieces and the InsideTracker page the record already uses, with the same about-ten-years-younger claim, and nothing dated 2026-10. Nothing in the window; the verify line about a missing update to his own-age claim is neither settled nor contradicted.

The session's search allowance (200 searches, shared by the twelve searchers of this first reading) ran out before a second search aimed at this record could be run.

Only one search could be run on 2026-10-17. It returned a priority review by David Barzilai in the journal Aging (volume 17, issue 1, pages 1 to 15, listed on PubMed as 39808121 and in PMC as PMC11810056, dated 2025-01 on the snippet) on his hyperfunction theory and rapamycin, the journal's call for papers for a commemorative collection, and his 2023 Oncotarget perspective; all before the window, and none gives his birth date or a start date for his own use, so neither verify line is settled. The programme ended with his death in 2024-10 and nothing seen changes that.

The session's search allowance (200 searches, shared by the twelve searchers of this first reading) ran out before a second search aimed at this record could be run.

Only one search could be run on 2026-10-17 and his podcast page could not be opened. The search returned his 2023-09 episode 272 with Sabatini and Kaeberlein, the 2023-05 and 2024-07 Huberman episodes (the record's own source), and nothing dated 2026-10. Nothing in the window; he still publishes a regimen and claims nothing about his own ageing on what was seen.

The session's search allowance (200 searches, shared by the twelve searchers of this first reading) ran out before a second search aimed at this record could be run.

Nothing in the window. The searches returned only the 2023 Guangzhou humanised-kidney embryos (Cell Stem Cell, 2023-09-07), the 2017 Wu and Izpisua Belmonte chimera paper, and a 2025-06 report of beating part-human hearts in pig embryos carried for 21 days, all of which the record already knows or which fall below the animal rung (no animal born with a working mostly-human organ).

Nothing in the window. The searches returned the 2016-12-13 approval, the 2024-08 arthroscopic-delivery label expansion (MACI Arthro) and older trial extensions, none of which bears on the wide-use rung (use in worn older joints); no osteoarthritis trial of grown cartilage cells and no new use figures were found. Vericel's own newsroom could not be opened because the session's web fetching was refused.

Nothing in the window. The searches returned the 2024-03-27 Nature paper the record rests on, no registered trial or first person, and one older related mouse paper: a Lund University group (David Bryder) reported in Nature Communications that clearing old mice's own blood stem cells with an antibody-toxin and transplanting young ones restored naive B and T cell output without chemotherapy; the search results dated the university's release to 2025-09-13 and a repost to 2026-07-23, so it is before the window either way, it is a transplant rather than a reset of the animal's own cells, and it bears on the animal rung the leaf has already reached, not on the first-human rung.

Nothing in the window. No filing for approval of Vertex's zimislecel, no acceptance by a regulator and no new peer-reviewed readout was found; the newest item seen was a third-party explainer dated 2026-06 saying a filing in 2026 was still expected, which matches the record's verify note (no filing as of 2026-08-03). The Parkinson's late-stage trial (bemdaneprocel, NCT06944522) showed no update after its 2025 start. Vertex's and BlueRock's newsrooms could not be opened because the session's web fetching was refused, so a release in the window cannot be ruled out by this searcher.

Nothing in the window. The searches returned older trachea follow-ups (the 2008 case's five-year report, a 2012 paediatric case), a 2022 oesophagus study in piglets, a 2025-11 report of a 3D-printed corneal implant in a phase 1 trial at Rambam in Haifa (cornea is a tissue and left out by the test), and a 2026-01 ARPA-H grant of 28.5 million dollars to a Carnegie Mellon team to develop a printed liver, which is funding, not an organ in a person.

The Upgrade Tree shows it at first human, which agrees.

Nothing in the window. The searches returned the EXPAND trial's first transplant (United Therapeutics, announced 2025-11-03, at NYU Langone, NCT06878560), which the record already knows as the first trial beginning in 2025-10, and coverage of Tim Andrews, whose pig kidney at Massachusetts General Hospital worked for 271 days from 2025-01-25 before removal in 2025-10 and a human kidney in 2026-01, reported in The Lancet on a date the search results did not show; neither is a regulator's approval for use outside a trial, which the next rung needs. United Therapeutics' and eGenesis' newsrooms could not be opened because the session's web fetching was refused, so a release in the window cannot be ruled out by this searcher.

The Upgrade Tree shows it at first human, which agrees.

Only one search could be run on 2026-10-17 and his site could not be opened. The search returned 2024 Spanish-language coverage of the 61-year-old-who-looks-38 kind and a podcast listing at age 62, all before the window and already covered by the record. Nothing in the window; the public record paragraph still holds on what was seen.

The session's search allowance (200 searches, shared by the twelve searchers of this first reading) ran out before a second search aimed at this record could be run.

Nothing in the window. No controlled trial of an interleukin-11 blocker on frailty, muscle or a validated clock in people was found, registered or reported, and no new animal lifespan report. The only 2026 item seen is a results posting on 2026-03-09 for a trial of the anti-interleukin-11-receptor antibody LASN01 in thyroid eye disease (ClinicalTrials.gov NCT06226545), which is before the window and not an age-related measure, so it does not bear on the first-human rung. A fourth search aimed at the trial registry for an ageing or sarcopenia trial of such an antibody could not be run because the shared search budget ran out.

Nothing in the window. No controlled trial of a microbial transfer in older people has reported, and no new animal report dated 2026-10-10 to 2026-10-17 was found. Two registered trials bear on the first-human rung and are already allowed for by the estimate's assumption of a trial running in older adults: ARMOR (ClinicalTrials.gov NCT06649981, registered 2024-10-21, capsules of gut microbes from young active donors or placebo in 65 to 84 year olds in Chile, with its protocol published in BMC Geriatrics volume 26 in 2026) and STEP-aging (NCT05598112, oral transfer for ageing at Fuwai Hospital in China, recruiting, primary completion estimated 2026-12-31). Neither has results, and whether either registry entry changed in the window could not be checked because the registry could not be opened from this session.

Nothing dated in the window 2026-10-10 to 2026-10-17 bears on the test. The nearest items are older: a Nature Aging report that changes over time in several clocks predict death in the InCHIANTI group (699 people, up to 24 years of follow-up; listed as about 218 days old, so roughly 2026-03, and below the test's thousand-person floor), a 2026 HUNT study (PubMed 42163406, date not seen) reporting the pace of ageing read from blood predicting death in two Norwegian groups, and an annotated bibliography of the Dunedin pace-of-ageing measure dated 2026-10-01, none of which could be opened. The leaf stays at first human, whose test is already met, and nothing seen touches the clinic rung (a regulator's clearance or a health system's published routine use).

No regulator's record in the window qualifies a marker of ageing or agrees one as a trial's main measure; every source seen says none has. The one item dated in the window is a trade commentary of 2026-10-14 (Clinical Trial Vanguard) saying proteomic clocks are being used as endpoints in some prospective trials while carrying no regulatory standing, which is not a regulator's act and could not be opened. Coverage of the ARDD 2026 meeting (about 2026-10-03, so before the window) reports United States regulator staff saying a predictive marker is not a surrogate until it responds to treatment and tracks risk across trials, and a registered Sheba Medical Center trial (NCT07596576, a protocol to lower biological age in older adults; date and primary measure not seen) names no regulator's agreement in the listing. The regulator's own qualification list, which the verify list asks to be checked, could not be opened from this session.

Nothing in the window: no regulator has approved a drug with ageing as its indication, and the TAME metformin trial has not started. Trade reports of 2026-09-26 (Technology Org and Innovita Research, titled 'TAME: the aging trial that never enrolled a patient') say the trial is still awaiting funding with no one enrolled, which is the same September 2026 coverage the record's verify list already rests on and which still could not be opened; a few consumer pages claiming enrolment is complete or on schedule were again judged unreliable. Coverage of the ARDD 2026 meeting (about 2026-10-03, before the window) says the United States regulator will name ageing and longevity among the topics of a forthcoming regulatory-science focus-areas document, which is a stated intention and not a rule, an approval or a written agreement.

Nothing dated in the window 2026-10-10 to 2026-10-17 bears on the test. The searches returned the 2023 Nature paper the leaf rests on, the 2025 Nature Medicine UK Biobank follow-up the verify list already names, a Nature Communications paper on the genetics of organ ageing in 51,936 UK Biobank people, and a paper titled 'Patterns of organ-specific proteomic aging in relation to lifestyle, diseases, and mortality' (PMC12686593, date, cohort and authors not seen) that may be a further independent group for the verify list's question and should be opened in a session that can reach PubMed Central. A Time profile of Tony Wyss-Coray from about 2026-08-20 says the company he co-founded, Vero Bioscience, is running clinical studies of the organ-age tests, which is neither a clearance nor a published routine practice. A third search for this leaf was not run because the shared search budget ran out.

Nothing in the window. No new pace-of-ageing reading by him was found; the only items that name the 0.64 figure are the WION report of his 2024-06-11 post, which the record already holds, and a Chinese-language newsletter of 2026-08 repeating it. The remaining results were undated, repetitive pages on featurespace.com and media-azi.md carrying contradictory numbers (a biological age of 31.4, a target under 0.70) with no source, and were not relied on. His newer statements of the goal are flagged under johnson-2023-biological-age-stays-the-same.

Only one search could be run on 2026-10-17; it returned nothing about her at all, only pages on the 2026 Winter Olympics and an unrelated athlete. Nothing in the window; the record's note that she publishes nothing of her own is consistent with the empty result but was not tested with a second wording.

The session's search allowance (200 searches, shared by the twelve searchers of this first reading) ran out before a second search aimed at this record could be run.

Only one search could be run on 2026-10-17 and his site could not be opened, so his October posts were not seen. The search returned 2023 and 2025 podcast listings (one placing him at the Tufts nutrition research centre, which bears on the second verify line but is a podcast biography, not a Tufts page) and a Lifespan.io piece on his microbial-burden book; nothing dated in the window. Neither verify line is settled.

The session's search allowance (200 searches, shared by the twelve searchers of this first reading) ran out before a second search aimed at this record could be run.

Only one search could be run on 2026-10-17 and the leaderboard itself could not be opened, so the 2026-10-16 top five in the record could not be re-read. The search returned an undated newsletter snapshot (1,750 participants, Bryan Johnson out of the top five at that time), a resolved prediction market on the 2025 year-end top spot, and unrelated Olympic Games pages; nothing dated in the window. The verify line on whether the laboratory checks a sample belongs to the named person is not settled.

The session's search allowance (200 searches, shared by the twelve searchers of this first reading) ran out before a second search aimed at this record could be run.

Nothing in the window; the bet is due in 2150. The results were the older coverage the record already rests on (The Scientist of 2001, Newswise, fightaging.org of 2018), plus a prediction-market page with no date. One detail the record does not carry, from the Newswise article, is that the winner is to be decided by a panel of three scientists chosen by the president of the American Association for the Advancement of Science; the page was not opened, so it is left here as a lead and not a correction. The verify item on Olshansky's own statement was not settled.

Nothing in the window; the claim is due in 2944. Results were the 2006 to 2017 coverage of the thousand-year line that the record already treats as coverage, and a New York Sun article (undated in the result, could not be opened) that mentions a declaration announced in early October without a year, which may or may not be this month. The most recent dated de Grey item found anywhere was a Provo meetup of 2026-08-12 and a stream of 2026-02, both outside the window.

Nothing in the window. The foundation's first mouse study is described in a 2026-08-12 meetup listing as complete, under analysis and a qualified win, and its page for the second study said it would begin in the second half of 2025 subject to funding; no peer-reviewed result and no start date for the second study were found, and the four-month figure the verdict rests on was not contradicted. The missed verdict stands.

Nothing in the window. No statement of the two-step form (fifteen years from robust mouse rejuvenation) was found at all in 2026; his recent statements, where found, are given as a flat horizon of about fifteen years, which is the matter of de-grey-2024-fifty-percent-twelve-to-fifteen-years. The mouse milestone the clock starts from has not been reported met.

Nothing in the window. The speaker died on 2024-08-01, as the record's who_is already implies, so no new statement is possible; the only 2026 mention was a podcast of 2026-04 that names the Hayflick limit in passing. The Nature essay's own page was not reached, so nothing new was checked against its abstract.

Nothing in the window. The searches returned the foundation's older items the record already knows (the 2023-12-02 report of forty million dollars at the first summit, the Al Arabiya report of 2025-02-04 of more than four hundred million dollars in grants in twenty months) and a crowd of unrelated companies with similar names; no statement by the foundation dated 2026-10-10 to 2026-10-17 was seen, and the foundation's own newsroom could not be opened from this session.

Nothing in the window: no interview, post or report by him dated 2026-10-10 to 2026-10-17 was found, and the search for the episode's transcript returned only the episode listing, not the text, so the fact on the verify list (the exact wording at about one hour thirty-three minutes) is still open. The same searches turned up 2026 coverage of him moving the date to around 2032, which is reported under kurzweil-2029-escape-velocity because that is the record with the headline flag and the due year.

Nothing in the window. The searches returned the Fight Aging! excerpt of 2004-11-17 that the record's verify list already cites, mid-2000s interviews about the three bridges (NBC News, PBS NewsHour), a sceptical review on skepdoc.info, and speaker-bureau pages for Terry Grossman; no statement by either author dated 2026-10-10 to 2026-10-17 was seen, and nothing bears on the verdict of missed.

Nothing in the window. The What we do page still appears in results with the sentence the record quotes, including the line that the goal was chosen to be falsifiable and testable; the other results are profile pages (Lifespan.io, GuideStar, Kindora, MarketScreener), a 2022 release on the ELONgevity Protection Project, and David Gobel's 2025 conference listing, none dated 2026-10-10 to 2026-10-17. The foundation's home page could not be opened from this session either, so the record's note of 2026-10-16 that it refused connections stands.

Nothing in the window. Both searches returned only coverage of the 2024-10-07 Nature Aging paper the record is built on (AFAR, Scientific American, the University of Illinois Chicago, Lifespan.io) and no later paper, statement or rebuttal by the author; the due year is 2100 and the verdict not-yet-due stands.

Nothing in the window. The searches returned the 2022 launch coverage of the ten-year aim (BioSpace, Freethink, the company's own feed) and secondary profiles; one aggregator (wewillcure.com) says the company plans a first human trial of its reprogramming programme in 2027, which is consistent with the record's note that the 2026-05-22 blog post planned first-in-human milestones for 2026 and 2027 and is not a new statement by the company. No new statement, withdrawal or date was seen; the verdict unfalsifiable stands. Nothing of the plasma programme entering people was seen.

Nothing in the window. The newest items seen were a University of Nicosia lecture of 2026-06-04 in Athens, reported under the headline There is no law of biology that says we have to age (Cyprus Mail 2026-07-02), an honorary doctorate there on 2026-06-05, and a Bucharest conference appearance on 2026-06-20; these restate the book's sentence without adding a date and fall before the window, so the verdict unfalsifiable stands.